SUPERNUS PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Accumulated Other Comprehensive Income of -$138.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-03
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$138.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$255.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$44.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$71.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$138.00K 10-Q · filed 2026-08-03 |
| 2026-03-31 | -$255.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$44.00K 10-Q · filed 2026-08-03 |
| 2025-09-30 | -$71.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$200.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$159.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$189.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $78.00K 10-Q · filed 2024-11-04 |
| 2024-06-30 | -$372.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$534.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$593.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$1.21M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$1.77M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$2.33M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$3.21M 10-Q · filed 2023-11-08 |
| 2022-09-30 | -$4.05M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$2.22M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$773.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.54M 10-K · filed 2023-03-09 |
| 2021-09-30 | $4.21M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $5.43M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $6.25M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $8.97M 10-K · filed 2022-04-13 |
| 2020-09-30 | $9.70M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $11.36M 10-Q · filed 2020-08-17 |
| 2020-03-31 | -$166.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $7.42M 10-K · filed 2021-03-08 |
| 2019-09-30 | $7.26M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $5.92M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.43M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$3.16M 10-K · filed 2020-02-28 |
| 2018-09-30 | -$4.11M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$4.12M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$2.29M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$747.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | $252.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $216.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $32.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$134.00K 10-K · filed 2018-03-01 |
| 2016-09-30 | $127.00K 10-Q · filed 2017-01-20 |
| 2016-06-30 | $549.00K 10-Q/A · filed 2017-01-23 |
| 2016-03-31 | $168.00K 10-Q/A · filed 2017-01-20 |
| 2015-12-31 | -$488.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | -$107.00K 10-Q/A · filed 2017-01-20 |
| 2015-06-30 | -$151.00K 10-Q/A · filed 2017-01-23 |
| 2015-03-31 | -$65.00K 10-Q/A · filed 2017-01-20 |
| 2014-12-31 | -$154.00K 10-Q/A · filed 2017-01-20 |
| 2014-09-30 | -$35.00K 10-Q/A · filed 2017-01-20 |
| 2014-06-30 | $1.00K 10-Q · filed 2014-08-12 |
| 2014-03-31 | $1.00K 10-Q · filed 2014-05-13 |
| 2013-09-30 | -$81.00K 10-Q · filed 2013-11-13 |
| 2013-06-30 | -$235.00K 10-Q · filed 2013-08-14 |
| 2013-03-31 | -$89.00K 10-Q · filed 2013-05-15 |
| 2012-12-31 | -$57.00K 10-K · filed 2014-03-21 |
| 2012-09-30 | -$29.00K 10-Q · filed 2012-11-02 |
| 2012-06-30 | $6.00K 10-Q · filed 2012-08-13 |
| 2012-03-31 | $8.00K 10-Q · filed 2012-06-08 |
| 2011-12-31 | $1.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |